Mithra Pharmaceuticals SA appoints Dr. David H Solomon as Chief Executive Officer starting on April 11th, 2023. This follows the assignment of Mr. Leon Van Rompay and an extensive, global search process for a successor. Dr. David H Solomon brings over 30 years of experience of strong strategic, operational, and innovation-minded leadership to Mithra.

He has a proven track record of successful RD pipeline delivery, strategic business development and deal making across multiple leading roles in the life sciences, biotechnology and pharmaceutical industries in the US and Europe. Dr. Solomon's appointment follows a thorough and selective process organized by the Nomination and Remuneration Committee with the assistance of Stanton Chase Executive Search. He was elected with unanimous approval of the Board of Directors.

Prior to joining Mithra, Dr. Solomon served as Chief Executive Officer of Pharnext Therapeutics. David oversaw the clinical development of Pharnext's lead product, PXT3003 in Charcot-Marie-Tooth disease type 1A which benefits from orphan drug status in Europe and the United States. Pharnext raised over USD 100 million in support of its programs while Dr. Solomon was CEO.

The company is fully recruited in its pivotal Phase III trial PREMIER in CMT1A with readout in Fourth Quarter 2023. Earlier, he was CEO of Silence Therapeutics plc. David restructured the company's management, streamlined corporate and RD operations and embarked on fundraising and business development agreements in support of the company's lead assets.

In July 2019, Silence Therapeutics announced the completion of a licensing and collaboration agreement with Mallinckrodt Pharmaceuticals, valued at up to USD 2.1 billion to advance gene-silencing medicines to treat complement-mediated diseases. During David's leadership of Silence Therapeutics, the share price increased over 10-fold. During his tenure as CEO at Zealand Pharma David helped build the company's novel proprietary pipeline of revolutionary medicines, raising USD 80 million, and completed agreements with Sanofi, Boehringer Ingelheim, Helsinn, AbbVie and Lilly.

While at Zealand Pharma, their first medicine - the GLP-1 receptor agonist lixisenatide in diabetes and obesity, now sold by Sanofi as Adlyxin, and in combination with Lantus as Soliqua- received sales and marketing approval. Dr. Solomon studied at the Weil Cornell Medical College and its Graduate School of Medical Sciences where he received his PhD. He was a faculty member at Columbia University's College of Physicians and Surgeons in the departments of Pharmacology, Neurology and Biological Sciences.

From 2003 to 2006, Dr. Solomon headed healthcare investing at Carrot Capital Healthcare Ventures in New York City.